NOS1 and intrahepatic cholangiocarcinoma: The first study found that GES in the setting of gastroparesis was found to decrease ICC, 5-HT2B receptor expression, 5-HT levels, nNOS neurons, CHAT neurons, and GDNF protein expression, which are all implicated in the disease progression [59].